National and Kapodistrian University of Athens
Μελέτη της γονιδιακής έκφρασης και των γονιδιακών οδών με cDNA μικροσυστοιχίες κατά τη διάγνωση και τη χημειοθεραπεία στην παιδική οξεία λεμφοβλαστική λευχαιμία
Abstract
dc:descriptionIntroduction: Hitherto, even though cure rates in childhood Acute Lymphoblastic Leukemia (ALL) reach 80% a subset of pediatric patients still relapse, exhibiting inferior prognosis. Consequently, emphasis could be placed on accurate identification of drug-resistant cases, elucidation of mechanisms underlying drug resistance and development of novel therapeutic strategies. Pharmacodynamic and pharmacogenomic studies are still carried out, even in well known drugs, to provide rational criteria for individualized therapy, enhanced efficacy and reduced toxicity. Aim & Objectives: This study was undertaken to develop a model system in order to investigate the effect of chemotherapy factors employed in childhood ALL therapy. Certain objectives included the study of: 1) Cell growth, apoptosis and necrosis under the effect of these drugs and 2) Gene expression profile (GEP) of treated cells in relation to cells’ nature and each drug’s dose. Materials and Methods: CCRF-CEM (T-leukemic cells) and CCRF-SB (B-leukemic cells) cell lines were used. A model system was created by treating cells with Prednisolone, Vincristine, L-Asparaginase, Daunomycin/Doxorubicin, Aracytine, Cyclophosphamide and Methotrexate, as those drugs are included in the induction phase of ALL treatment. Cell growth, cycle, necrosis and apoptosis were studied using flow cytometry, whilst gene differential expression was determined by microarrays. Microarray data analyses were statistically performed using Matlab simulation environment. The differentially expressed genes were identified with Gene Ontology Database. Results: The CCRF-CEM cells exhibited a biphasic reaction to prednisolone; with induction of mitosis following the application of small doses and necrosis after higher. The cell line proved to be resistant to Prednisolone. The differentially expressed genes that were determined included RTN4R, NEFL, CHEK1, SYCE1L, ITIH, B3GAT3, TTC3, RTN4R, CYP1A1 and HOXA13, which have been generally associated with neural development, regulation of neuronal axon’ construction, cell cycle functions, metabolism of glucosamine/glycanes, negative regulation of cell growth as well as activation of catabolism and recycling of proteins. The differentially expressed genes between the two cell lines treated with prednisolone, included FICD, PREX, LIAS, TPK, which take part in the regulation of the Rho proteins signalling pathway and the regulation of biosynthetic co-enzymes. The CCRF-CEM cells proved to be sensitive to Vincristine. The differentially expressed genes identified were NEFL, SHARPIN, RTN4R, UBB, HTT, MBP and ACSBG1, which have been related to the regulation of cell death and neuronal development functions. Cell proliferation was terminated following treatment with Doxorubicin/Daunomycin. The microarray study revealed the SLC12A8, SEC61G, SLC26A4, TRPM5Τ, NEFL, TIAM2, FANCA, LFNG genes that take part in transmembrane transportation, regulation of cell death and M phase in the meiotic cycle. The CCRF-CEM cells also proved to be sensitive to Aracytine. The differentially expressed genes FICD, TIAM2, NDUFS1, ATB2B4 detected following application of microarrays were dose dependent to the drug. All have been related to the Rho proteins signalling pathway and the biosynthesis and metabolism of nucleotides. Other differentially expressed genes including MYT1L, IRX6 and TBX1 were found to be involved in the regulation of RNA metabolism. Interestingly, CCRF-CEM cells proved to be resistant to Methotrexate. The differentially expressed genes identified from the microarray study were KLK6, MBP, RTN4R, NEFL, CHEK1 and CAMK2G, which normally participate in the regulation activities of the central nervous system and protein phosphorylation. Common genes that were differentially expressed between the two cell lines following treatment with Aracytine were SOS2, FICD, TIAM2, PREX1, SPATA13, ADAM9 and ADORA1. These genes were related to the Rho proteins signalling pathway and the MAPK signalling pathway. Further differentially expressed genes that were detected between these two cell lines and in correlation with anthracyclines’ treatment included ATF6, IKZF2, PRKDC, HDAC2 and TFEB, which are encoding proteins that participate in the transcription process. Following methotrexate treatment the differentially expressed genes were related to the MAPK signalling pathway. Accordingly, during the performance of vincristine experiments, the differentially expressed genes were related to cell death, calcium channels and neuronal morphogenesis. Conclusions: The over expression or down-regulation of certain genes suggested that the aforementioned mechanisms or functions are activated or deactivated in leukemic cells as a reaction to these drugs. These gene expression alterations could explain the cells’ resistance or sensitivity to treatment. The identified genes could potentially represent prognostic factors or therapeutic targets. In general, the application of the above model might lead to individualized therapeutic interventions to increase drug efficacy and reduce toxicity.
Degree
thesis:*- Grantor dc:publisher
- National and Kapodistrian University of Athens
- Year dc:date
- 2011
Author and committee
dc:creator, dc:contributor.*- Authors dc:creator
-
- Koultouki, Eleftheria
- Κουλτούκη, Ελευθερία
Subjects
dc:subject × 20- Γονιδιακή έκφραση
- cDNA μικροσυστοιχίες
- Οξεία λεμφοβλαστική λευχαιμία
- Παιδική ηλικία
- Χημειοθεραπευτικοί παράγοντες
- Κυτταρικός κύκλος
- Απόπτωση
- Νέκρωση
- Gene expression
- cDNA microarrays
- Acute lymphoblastic leukemia
- Childhood
- Chemotherapeutic factors
- Cell cycle
- Apoptosis
- Necrosis
- Ιατρική και Επιστήμες Υγείας
- Ιατρική Βιοτεχνολογία
- Medical and Health Sciences
- Medical Biotechnology
Rights
- Language dc:language
- gre
Identifiers
dc:identifier.*- Identifier
- 10.12681/eadd/27923